Agendia to Present Five Posters Demonstrating the Expanding Clinical Utility of MammaPrint + BluePrint at the 2025 San Antonio Breast Cancer Symposium
New data from the ongoing FLEX Study highlight the value of real-world evidence in personalizing chemotherapy decisions and improving outcomes in early-stage breast cancer
Agendia®, Inc., a leader in precision oncology for breast cancer, today announced it will present new results from the ongoing real-world FLEX Study (NCT03053193) at the 2025 San Antonio Breast Cancer Symposium (SABCS), taking place December 9-12 in San Antonio, Texas.
The company will present five posters, led by Agendia investigators and independent academic collaborators, that collectively highlight the broad clinical impact of MammaPrint® + BluePrint® genomic profiling in optimizing treatment decisions and improving outcomes for patients with hormone receptor positive, HER2-negative (HR+/HER2–) early breast cancer (EBC).
“We look forward to sharing these new findings from the FLEX Study, which spans more than 20,000 participants across 100 global sites, making it the largest and most diverse real-world evidence cohort for early-stage breast cancer,” said William Audeh, M.D., Chief Medical Officer at Agendia. “These results underscore our commitment to generating robust clinical evidence in settings beyond traditional clinical trials, ensuring the results can inform personalized treatment decisions across diverse patient populations and everyday clinical practice.”
The full list of abstracts & poster presentations is as follows:
3.2yr Updated Outcome Analysis of ACT-T Benefit by MammaPrint Risk Result
Improved 3-year IDFS with anthracycline-based therapy for patients with 70-gene signature High 2, Luminal B, HR+HER2– EBC
Poster #PS2-07-03 | Dec. 10, 5:00 PM - 6:30 PM | Presenter: Joyce O'Shaughnessy
MammaPrint Provides Stronger Prognostic Value Than Histologic Grade
70-gene signature high risk classification provides stronger prognostic value than histologic grade in HR+HER2– EBC
Poster #PS5-04-19 | Dec. 12, 12:30-2:00 PM | Presenter: Erin Cobain
Older Patients with Aggressive Breast Cancer May Benefit from Chemotherapy
HR+HER2– Patients Aged ≥70 with High Risk MammaPrint Benefit from Chemotherapy
Poster #PS3-08-17 | Dec. 11, 12.30 PM - 2 PM | Presenter: Reshma Mahtani
Understanding Breast Cancer in Overweight Latin American Patients
Distinct Immune and Metabolic Profiles in Latin American Breast Cancer Patients with Obesity
Poster #PS4-09-09 | Dec. 11, 5:00 PM - 6:30 PM | Presenter: Marcela Mazo Canola
30,000-Patient Study Expanding to Improve Breast Cancer Outcomes
FLEX: From Genomic Profiling to Real-World Insights in 30,000 Patients with Early-Stage Breast Cancer
Poster #PS5-09-19 | Dec. 12 12:30-2:00 PM | Presenter: Linsey P. Gold
About Agendia
Agendia is a global leader in precision oncology focused on early-stage breast cancer. The company’s genomic assays, MammaPrint + BluePrint, deliver essential biological insights to inform personalized treatment decisions for patients and their care teams. With operations in Amsterdam and Irvine, Agendia partners with academic and community oncology centers worldwide to generate real-world evidence through the landmark FLEX Study (NCT03053193), the largest whole-transcriptome registry of early-stage breast cancer.
About MammaPrint
MammaPrint is a clinically validated genomic test that analyzes the expression of 70 genes in breast cancer tissue to determine the likelihood of distant metastasis. By providing risk stratification into four categories — UltraLow Risk, Low Risk, High Risk 1, and High Risk 2 — MammaPrint enables more personalized, data-driven guidance to chemotherapy and endocrine therapy planning.
About BluePrint
BluePrint is a 80-gene molecular subtyping assay that reveals the underlying biology driving tumor growth, classifying tumors as Luminal-type, HER2-type, or Basal-type. By defining intrinsic subtypes beyond conventional pathology, BluePrint offers deeper biological understanding to refine therapeutic decision-making and enhance clinical outcomes.
View source version on businesswire.com: https://www.businesswire.com/news/home/20251104247663/en/
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
PennAero and Tinicum Announce Acquisition of TriMas Aerospace4.11.2025 20:17:00 CET | Press release
Tinicum, L.P. (“Tinicum”) today announced that one of its affiliates has signed an agreement to acquire the aerospace assets of TriMas Corporation (“TriMas Aerospace”), through which TriMas Aerospace will be merged with PennAero, a Tinicum portfolio company (“the Transaction”). Funds managed by Blackstone will be a minority investor in the Transaction. This investment reinforces PennAero’s strategy of partnering with its customers to provide best-in-class engineering, manufacturing, customer service and support. TriMas Aerospace is a leading provider of highly engineered fasteners and precision-machined components for mission-critical applications across the global commercial aerospace and defense industries. Backed by a portfolio of trusted brands, including Monogram Aerospace Fasteners™, Allfast Fastening Systems®, Mac Fasteners™, TFI Aerospace, TriMas Aerospace Germany, Martinic Engineering™, RSA Engineered Products™ and Weldmac Manufacturing Company, TriMas Aerospace delivers innov
BOSTON ONCOLOGY ARABIA and LOCAL CONTENT & GOVERNMENT PROCUREMENT AUTHORITY Sign Agreement to Localize Advanced Biologic Medicines in Saudi Arabia4.11.2025 19:50:00 CET | Press release
In a major step toward advancing pharmaceutical local content and national drug security, BOSTON ONCOLOGY ARABIA and the Local Content & Government Procurement Authority (LCGPA) have signed an agreement to localize the manufacture of two biosimilar medicines within the Kingdom. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251104239476/en/ Representatives from the Local Content & Government Procurement Authority (LCGPA) and Boston Oncology Arabia at the Global Health Exhibition 2025 in Riyadh, following the signing of an agreement to localize the manufacturing of advanced biologic medicines. The partnership builds on Boston Oncology Arabia’s fully integrated Saudi operations and its leadership in transferring global biopharma expertise to strengthen national drug security, expand local value creation, and deliver sustainable access to high-quality biologic therapies in line with Vision 2030. The signing ceremony took place
ClickHouse Acquires LibreChat to Democratize AI-Driven Analytics Through the Open-Source Agentic Data Stack4.11.2025 18:00:00 CET | Press release
ClickHouse, Inc., the company behind the world’s fastest and most popular real-time analytics database, today announced the acquisition of LibreChat, a leading open-source AI chat platform that provides a unified interface for interacting with large language models (LLMs). The acquisition brings LibreChat founder Danny Avila and his team to ClickHouse. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251104505230/en/ ClickHouse acquires LibreChat: Introducing the open-source Agentic Data Stack Together, ClickHouse and LibreChat form the foundation of the open-source Agentic Data Stack, empowering teams to deploy AI agents that analyze and act on large datasets through natural language. This shift to agentic analytics is already transforming how organizations such as Shopify, Daimler Truck, Fetch, and cBioPortal leverage their data, demonstrating the immediate value in real-world applications. At Shopify, LibreChat has become c
Mouser Electronics Explores the Future of Advanced Air Mobility and Its Impact on Design4.11.2025 17:37:00 CET | Press release
Mouser Electronics, Inc., the authorized global distributor with the newest electronic components and industrial automation products, released its latest installment of the Empowering Innovation Together (EIT) technology series, Urban Transport Takes Flight, examining the emerging sector of Advanced Air Mobility (AAM). This series details the technology behind electric vertical takeoff and landing (eVTOL) vehicles, the challenges of infrastructure for city deployment, and the hydrogen fuel cell solutions that power the future of urban transport. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251104083206/en/ Mouser explores the technology behind urban air mobility (UAM) vehicles, the challenges of infrastructure, and the fuel solutions that are powering the future of urban transport. The path for Urban Air Mobility (UAM) to transition from futuristic concept to scalable reality is constrained by barriers in form, power, and
Sparkle Clean Tech and Aquadei Launch Global Alliance to Transform Oil & Gas Water Treatment with Next-Gen Nanobubble Technology4.11.2025 17:02:00 CET | Press release
Sparkle Clean Tech (SCT)(exclusive global licensee of Siemens Energy’s oil & gas water-treatment IP) and Aquadei, LLC have formed a strategic alliance to deploy Aquadei’s proprietary nanobubble and hydrodynamic cavitation technologies to oil & gas operations globally. This partnership is set to drive advanced water treatment methods, delivering measurable operational, economic and environmental benefits across the industry. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251104652683/en/ Nanobubble Technology in Oil & Gas: Performance Advantages Nanobubbles (gas particles smaller than 200 nanometers) feature extraordinary physical surface and interfacial properties that enhance how oil and solids interact in water. When paired with SCT’s separation technologies, these ultrafine bubbles enable more efficient separation, lower chemical consumption, and greater process stability. Unlike traditional flotation systems that rely on
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom